Cat. No.: HY-13001

Quizartinib

Name: Quizartinib
Brand: MedChemExpress
SKU: HY-13001
Price: 33.00 USD
Availability: InStock
Rating: 5 (49 reviews)

(Synonyms: AC220)

49 Cited Publications

Avis client

Based on 49 publication(s) in Google Scholar

Quizartinib (AC220) is an orally active, potent and selective FLT3 inhibitor. Quizartinib inhibits kinase activity of mutant-FLT3, -PDGFRA and -KIT isoforms and inhibits autophosphorylation. Quizartinib inhibits cellular proliferation, induces apoptosis in cancer cells. Quizartinib can be used for the research of cancer.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté : 99.08%
CAS No.: 950769-58-1
Formule: C₂₉H₃₂N₆O₄S
Masse moléculaire:560.67

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Quizartinib Chemical Structure

CAS No.: 950769-58-1

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Essai clinique
Chemical Information
Publications (49)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole (7)
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

Kd: 1.6±0.7 nM (Flt3)^[1]

Voir tous les produits spécifiques à Isoform PDGFR :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	>10000 nM Compound: AC220	Toxicity against human A375 cells after 72 hrs by cell titer-blue assay Toxicity against human A375 cells after 72 hrs by cell titer-blue assay	[PMID: 19654408]
BaF3	GI₅₀	<0.0003 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells expressing TEL-fused FLT3 kinase after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells expressing TEL-fused FLT3 kinase after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	<0.0003 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-D835H mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-D835H mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	<0.0003 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	<0.0003 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835A mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835A mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	<0.0003 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835G mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835G mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	<0.0003 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835N mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835N mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	>10 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.002 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-D835Y mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-D835Y mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.0044 μM Compound: 7	Antiproliferative activity against TEL-fused PDGFRbeta-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused PDGFRbeta-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.011 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-D835V mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-D835V mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.012 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835del mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835del mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.017 μM Compound: 7	Antiproliferative activity against TEL-fused cKIT-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused cKIT-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.024 μM Compound: 7	Antiproliferative activity against TEL-fused CSF1R-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused CSF1R-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.028 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835Y mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835Y mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.056 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835I mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835I mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.11 μM Compound: 7	Antiproliferative activity against TEL-fused DDR2-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused DDR2-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.12 μM Compound: 7	Antiproliferative activity against TEL-fused DDR1-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused DDR1-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.13 μM Compound: 7	Antiproliferative activity against TEL-fused RET-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused RET-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.27 μM Compound: 7	Antiproliferative activity against TEL-fused FLT4-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused FLT4-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.37 μM Compound: 7	Antiproliferative activity against mouse BAF3 cells harboring FLT3-K663Q mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-K663Q mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	0.4 μM Compound: 7	Antiproliferative activity against TEL-fused LCK-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused LCK-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	<0.0003 μM Compound: 7	Antiproliferative activity against TEL-fused PDGFRalpha-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused PDGFRalpha-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	<0.3 nM Compound: 7	Antiproliferative activity against TEL-fused PDGFRalpha-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against TEL-fused PDGFRalpha-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
BaF3	GI₅₀	1.452 μM Compound: Quiz	Growth inhibition of mouse BA/F3 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of mouse BA/F3 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
BaF3	IC₅₀	>1000 nM Compound: AC220	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-F691L mutant measured after 72 hrs by MTT assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-F691L mutant measured after 72 hrs by MTT assay	[PMID: 30939008]
BaF3	IC₅₀	4.94 nM Compound: AC220	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD mutant measured after 72 hrs by MTT assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD mutant measured after 72 hrs by MTT assay	[PMID: 30939008]
BaF3	IC₅₀	>1000 nM Compound: AC220	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835V mutant measured after 72 hrs by MTT assay Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835V mutant measured after 72 hrs by MTT assay	[PMID: 30939008]
BaF3	GI₅₀	4.8 μM Compound: Quizartinib	Growth inhibition of mouse BA/F3 cells assessed as inhibition of cell growth incubated for 72 hrs by Cell-titer-Glo assay Growth inhibition of mouse BA/F3 cells assessed as inhibition of cell growth incubated for 72 hrs by Cell-titer-Glo assay	[PMID: 31513411]
BaF3	GI₅₀	0.3 nM Compound: 3	Inhibition of FLT3 ITD mutant expressed in human BaF3 cells assessed as reduction in cell growth incubated for 72 hrs by CCK8 assay Inhibition of FLT3 ITD mutant expressed in human BaF3 cells assessed as reduction in cell growth incubated for 72 hrs by CCK8 assay	[PMID: 32832025]
BaF3	GI₅₀	1659.5 nM Compound: 3	Cytotoxicity against human BAF3 cells assessed as growth inhibition incubated for 72 hrs by CCK8 assay Cytotoxicity against human BAF3 cells assessed as growth inhibition incubated for 72 hrs by CCK8 assay	[PMID: 32832025]
BaF3	IC₅₀	9312.2 nM Compound: AC220	Cytotoxicity against mouse BaF3 cells assessed as reduction in cell viability Cytotoxicity against mouse BaF3 cells assessed as reduction in cell viability	[PMID: 32891702]
BaF3	GI₅₀	>10000 nM Compound: AC-220	Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691I mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691I mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	GI₅₀	0.6 nM Compound: AC-220	Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	GI₅₀	12.9 nM Compound: AC-220	Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	GI₅₀	2.2 nM Compound: AC-220	Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	GI₅₀	68.2 nM Compound: AC-220	Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691L mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691L mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	GI₅₀	>10000 nM Compound: AC-220	Antiproliferative activity against mouse Ba/F3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse Ba/F3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
BaF3	IC₅₀	133.2 nM Compound: 8	Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-F691L mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiterGlo luminescent assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-F691L mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiterGlo luminescent assay	[PMID: 34550682]
BaF3	IC₅₀	14.97 nM Compound: 8	Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-Y842H mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-Y842H mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay	[PMID: 34550682]
BaF3	IC₅₀	27.09 nM Compound: 8	Antiproliferative activity against mouse BaF3 cells harboring FLT3-TEL-D835V mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-TEL-D835V mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay	[PMID: 34550682]
BaF3	IC₅₀	3.52 nM Compound: 8	Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay	[PMID: 34550682]
BaF3	IC₅₀	49.63 nM Compound: 8	Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-D835V mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-D835V mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay	[PMID: 34550682]
BaF3	IC₅₀	5.41 nM Compound: 8	Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-N676D mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-N676D mutant assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay	[PMID: 34550682]
BaF3	IC₅₀	>1000 nM Compound: 8	Antiproliferative activity against mouse BaF3 cells assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay Antiproliferative activity against mouse BaF3 cells assessed as reduction in cell viability measured after 72 hrs by CellTiterGlo luminescent assay	[PMID: 34550682]
BaF3	IC₅₀	121 nM Compound: Quizartinib	Antiproliferative activity against mouse BaF3 cells harboring FLT3-D835F mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-D835F mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 36638621]
BaF3	IC₅₀	2 nM Compound: Quizartinib	Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 36638621]
BaF3	IC₅₀	37 nM Compound: Quizartinib	Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD/D835Y mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD/D835Y mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 36638621]
BaF3	IC₅₀	381 nM Compound: Quizartinib	Antiproliferative activity against mouse BaF3 cells harboring FLT3-F691L mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-F691L mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 36638621]
BaF3	IC₅₀	86 nM Compound: Quizartinib	Antiproliferative activity against mouse BaF3 cells harboring FLT3-D835V mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-D835V mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 36638621]
BaF3	IC₅₀	>10 μM Compound: AC220	Cytotoxicity against mouse BaF3 cells assessed as inhibition of cell growth incubated for 72 hrs Cytotoxicity against mouse BaF3 cells assessed as inhibition of cell growth incubated for 72 hrs	[PMID: 37163951]
BaF3	IC₅₀	0.001 μM Compound: AC220	Antiproliferative activity against mouse BaF3 cells harboring FLT3 ITD mutant assessed as inhibition of cell growth incubated for 72 hrs Antiproliferative activity against mouse BaF3 cells harboring FLT3 ITD mutant assessed as inhibition of cell growth incubated for 72 hrs	[PMID: 37163951]
BaF3	IC₅₀	0.093 μM Compound: AC220	Antiproliferative activity against mouse BaF3 cells harboring FLT3 ITD/D835V mutant assessed as inhibition of cell growth incubated for 72 hrs Antiproliferative activity against mouse BaF3 cells harboring FLT3 ITD/D835V mutant assessed as inhibition of cell growth incubated for 72 hrs	[PMID: 37163951]
BaF3	IC₅₀	0.1 μM Compound: AC220	Antiproliferative activity against mouse BaF3 cells harboring FLT3 D835V mutant assessed as inhibition of cell growth incubated for 72 hrs Antiproliferative activity against mouse BaF3 cells harboring FLT3 D835V mutant assessed as inhibition of cell growth incubated for 72 hrs	[PMID: 37163951]
BaF3	IC₅₀	0.133 μM Compound: AC220	Antiproliferative activity against mouse BaF3 cells harboring FLT3 ITD/F691L mutant assessed as inhibition of cell growth incubated for 72 hrs Antiproliferative activity against mouse BaF3 cells harboring FLT3 ITD/F691L mutant assessed as inhibition of cell growth incubated for 72 hrs	[PMID: 37163951]
BaF3	IC₅₀	2.9 nM Compound: Quizartinib	Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-N701K mutation assessed as reduction in cell viability incubated for 72 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay Antiproliferative activity against mouse BaF3 cells harboring FLT3-ITD-N701K mutation assessed as reduction in cell viability incubated for 72 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay	[PMID: 37584545]
BaF3	IC₅₀	0.38 nM Compound: Quizartinib	Antiproliferative activity against mouse BaF3 cells expressing FLT3 ITD mutant assessed as inhibition of cell growth incubated for 72 hrs by absorbance based microplate reader Antiproliferative activity against mouse BaF3 cells expressing FLT3 ITD mutant assessed as inhibition of cell growth incubated for 72 hrs by absorbance based microplate reader	[PMID: 38389894]
BaF3	IC₅₀	128.8 nM Compound: Quizartinib	Antiproliferative activity against mouse BaF3 cells expressing FLT3 F691L mutant assessed as inhibition of cell growth incubated for 72 hrs by absorbance based microplate reader Antiproliferative activity against mouse BaF3 cells expressing FLT3 F691L mutant assessed as inhibition of cell growth incubated for 72 hrs by absorbance based microplate reader	[PMID: 38389894]
BaF3	IC₅₀	146.6 nM Compound: Quizartinib	Antiproliferative activity against mouse BaF3 cells expressing FLT3 D835V mutant assessed as inhibition of cell growth incubated for 72 hrs by absorbance based microplate reader Antiproliferative activity against mouse BaF3 cells expressing FLT3 D835V mutant assessed as inhibition of cell growth incubated for 72 hrs by absorbance based microplate reader	[PMID: 38389894]
BaF3	IC₅₀	152.4 nM Compound: Quizartinib	Antiproliferative activity against mouse BaF3 cells expressing FLT3 D835F mutant assessed as inhibition of cell growth incubated for 72 hrs by absorbance based microplate reader Antiproliferative activity against mouse BaF3 cells expressing FLT3 D835F mutant assessed as inhibition of cell growth incubated for 72 hrs by absorbance based microplate reader	[PMID: 38389894]
BaF3	IC₅₀	25.53 nM Compound: Quizartinib	Antiproliferative activity against mouse BaF3 cells expressing FLT3 ITD D835Y mutant assessed as inhibition of cell growth incubated for 72 hrs by absorbance based microplate reader Antiproliferative activity against mouse BaF3 cells expressing FLT3 ITD D835Y mutant assessed as inhibition of cell growth incubated for 72 hrs by absorbance based microplate reader	[PMID: 38389894]
BJ	GI₅₀	>40 μM Compound: Quizartinib	Cytotoxicity against human BJ cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against human BJ cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
CCRF-CEM	GI₅₀	>40 μM Compound: Quizartinib	Cytotoxicity against human CEM cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against human CEM cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
CMK	GI₅₀	0.12 μM Compound: 7	Antiproliferative activity against human CMK cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human CMK cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
EOL1	GI₅₀	<0.0005 μM Compound: Quizartinib	Cytotoxicity against FIP1L1-PDGFRA positive human EOL-1 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against FIP1L1-PDGFRA positive human EOL-1 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
EOL1	GI₅₀	<0.5 nM Compound: Quizartinib	Cytotoxicity against FIP1L1-PDGFRA positive human EOL-1 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against FIP1L1-PDGFRA positive human EOL-1 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
EOL1	IC₅₀	0.0001 nM Compound: 7; AC220	Cytotoxicity against human EOL1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human EOL1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
EOL1	GI₅₀	<0.001 μM Compound: Quizartinib	Antiproliferative activity against human EOL1 cells expressing IP1L1-PDGFRA fusion protein Antiproliferative activity against human EOL1 cells expressing IP1L1-PDGFRA fusion protein	[PMID: 35124201]
HCC827	GI₅₀	>5 μM Compound: Quiz	Growth inhibition of human HCC827 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of human HCC827 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
HCC827	GI₅₀	>40 μM Compound: Quizartinib	Cytotoxicity against human HCC827 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against human HCC827 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
HL-60	GI₅₀	8.014 μM Compound: AC220	Growth inhibition of human HL60 cells after 48 hrs by XTT assay Growth inhibition of human HL60 cells after 48 hrs by XTT assay	[PMID: 25108079]
HL-60	GI₅₀	1.488 μM Compound: AC220	Growth inhibition of human HL60 cells expressing wild type FLT-3 after 48 hrs by XTT assay Growth inhibition of human HL60 cells expressing wild type FLT-3 after 48 hrs by XTT assay	[PMID: 27187860]
HL-60	GI₅₀	>10 μM Compound: AC220	Growth inhibition of human HL60 cells harboring wild-type FLT3 by CCK8 assay Growth inhibition of human HL60 cells harboring wild-type FLT3 by CCK8 assay	[PMID: 28043794]
HL-60	GI₅₀	0.13 μM Compound: 7	Antiproliferative activity against human HL60 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human HL60 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
HL-60	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
HL-60	GI₅₀	>3000 nM Compound: 3	Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 32832025]
HL-60	IC₅₀	>100 μM Compound: AC220	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
HL-60	IC₅₀	771.2 nM Compound: AC220	Antiproliferative activity against human HL-60 cells expressing low level wild type FLT3 assessed as inhibition of cell growth Antiproliferative activity against human HL-60 cells expressing low level wild type FLT3 assessed as inhibition of cell growth	[PMID: 37163951]
HT-22	EC₅₀	193.6 nM Compound: AC220; F13	Inhibition of TNFalpha-induced necroptosis in mouse HT-22 cells incubated for 24 hrs Inhibition of TNFalpha-induced necroptosis in mouse HT-22 cells incubated for 24 hrs	[PMID: 38199165]
IM-9	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human IM-9 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human IM-9 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
K562	GI₅₀	>10 μM Compound: AC220	Growth inhibition of human K562 cells after 48 hrs by XTT assay Growth inhibition of human K562 cells after 48 hrs by XTT assay	[PMID: 25108079]
K562	GI₅₀	>20 μM Compound: 3, AC220	Inhibition of wild type BCR/ABL in FLT3 deficient human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay Inhibition of wild type BCR/ABL in FLT3 deficient human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 26081023]
K562	GI₅₀	2.638 μM Compound: AC220	Growth inhibition of human K562 cells after 48 hrs by XTT assay Growth inhibition of human K562 cells after 48 hrs by XTT assay	[PMID: 27187860]
K562	IC₅₀	>10000 nM Compound: AC220	Antiproliferative activity against FLT3-deficient human K562 cells after 72 hrs by MTT assay Antiproliferative activity against FLT3-deficient human K562 cells after 72 hrs by MTT assay	[PMID: 27266526]
K562	GI₅₀	>10 μM Compound: AC220	Growth inhibition of FLT3 null human K562 cells by CCK8 assay Growth inhibition of FLT3 null human K562 cells by CCK8 assay	[PMID: 28043794]
K562	GI₅₀	>20 μM Compound: Quiz	Growth inhibition of human K562 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of human K562 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
K562	GI₅₀	>40 μM Compound: Quizartinib	Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis	[PMID: 31514019]
K562	IC₅₀	10.33 μM Compound: AC220	Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31614258]
K562	IC₅₀	>20 μM Compound: Quizartinib	Antiproliferative activity against human K562 cells assessed as cell death measured after 72 hrs by resazurin dye based assay Antiproliferative activity against human K562 cells assessed as cell death measured after 72 hrs by resazurin dye based assay	[PMID: 34288692]
K562	GI₅₀	>20 μM Compound: Quizartinib	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	[PMID: 35124201]
K562	IC₅₀	>100 μM Compound: AC220	Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
K562	IC₅₀	291.4 nM Compound: AC220	Antiproliferative activity against human K562 cells deficit of oncogenic FLT3 assessed as inhibition of cell growth Antiproliferative activity against human K562 cells deficit of oncogenic FLT3 assessed as inhibition of cell growth	[PMID: 37163951]
Kasumi 1	GI₅₀	0.064 μM Compound: Quiz	Growth inhibition of human Kasumi-1 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of human Kasumi-1 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
Kasumi 1	GI₅₀	0.064 μM Compound: Quizartinib	Antiproliferative activity against human Kasumi 1 cells harboring N822K KIT mutant Antiproliferative activity against human Kasumi 1 cells harboring N822K KIT mutant	[PMID: 35124201]
Kasumi 1	GI₅₀	0.01 μM Compound: Quizartinib	Antiproliferative activity against human Kasumi 1 cells harboring KIT N822K mutant assessed as cell growth inhibition by resorufin dye based fluorescence analysis Antiproliferative activity against human Kasumi 1 cells harboring KIT N822K mutant assessed as cell growth inhibition by resorufin dye based fluorescence analysis	[PMID: 37535845]
KCL-22	IC₅₀	>100 μM Compound: AC220	Antiproliferative activity against human KCL-22 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human KCL-22 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
KG-1	IC₅₀	0.16 nM Compound: 7; AC220	Cytotoxicity against human KG-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human KG-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
KG-1	GI₅₀	2212.1 nM Compound: 3	Cytotoxicity against human KG1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity against human KG1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 32832025]
KG-1	IC₅₀	33.53 μM Compound: AC220	Antiproliferative activity against human KG-1 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human KG-1 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
KG-1a	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human KG-1a cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human KG-1a cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
KG-1a	IC₅₀	>100 μM Compound: AC220	Antiproliferative activity against human KG-1a cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human KG-1a cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
KMOE-2	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human KMOE-2 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human KMOE-2 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
L-363	IC₅₀	0.181 nM Compound: 7; AC220	Cytotoxicity against human L-363 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human L-363 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
MCF7	GI₅₀	>20 μM Compound: Quiz	Growth inhibition of human MCF7 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of human MCF7 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
MEF	EC₅₀	66.52 μM Compound: AC220; F13	Inhibition of TNFalpha-induced necroptosis in mouse MEF cells incubated for 24 hrs Inhibition of TNFalpha-induced necroptosis in mouse MEF cells incubated for 24 hrs	[PMID: 38199165]
ML-2	IC₅₀	0.419 nM Compound: 7; AC220	Cytotoxicity against human ML-2 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human ML-2 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
MOLM-13	GI₅₀	4 nM Compound: 1, AC220	Antiproliferative activity against human MOLM13 cells expressing FLT3-ITD mutant Antiproliferative activity against human MOLM13 cells expressing FLT3-ITD mutant	[PMID: 22726931]
MOLM-13	GI₅₀	0.004 μM Compound: 3, AC220	Inhibition of FLT3 ITD heterozygous mutant in human MOLM-13 cells assessed as cell growth inhibition after 72 hrs by MTS assay Inhibition of FLT3 ITD heterozygous mutant in human MOLM-13 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 26081023]
MOLM-13	GI₅₀	<0.0003 μM Compound: 7	Antiproliferative activity against human MOLM13 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MOLM13 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
MOLM-13	GI₅₀	<0.3 nM Compound: 7	Antiproliferative activity against human MOLM13 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MOLM13 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
MOLM-13	GI₅₀	0.002 μM Compound: Quiz	Growth inhibition of human MOLM13 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of human MOLM13 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
MOLM-13	IC₅₀	1.885 nM Compound: AC220	Antiproliferative activity against human MOLM13 cells harboring FLT3-ITD mutant measured after 72 hrs by MTT assay Antiproliferative activity against human MOLM13 cells harboring FLT3-ITD mutant measured after 72 hrs by MTT assay	[PMID: 30939008]
MOLM-13	IC₅₀	0.007 nM Compound: 7; AC220	Cytotoxicity against human MOLM-13 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human MOLM-13 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
MOLM-13	GI₅₀	1.5 nM Compound: 3	Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 32832025]
MOLM-13	IC₅₀	2.4 nM Compound: Quizartinib	Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 34583130]
MOLM-13	IC₅₀	1.1 nM Compound: Quizartinib	Anticancer activity against human MOLM-13 cells expressing heterogenous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay Anticancer activity against human MOLM-13 cells expressing heterogenous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay	[PMID: 35033885]
MOLM-13	IC₅₀	0.003 μM Compound: AC220	Antiproliferative activity against human MOLM-13 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human MOLM-13 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
MOLM-13	IC₅₀	15.2 nM Compound: AC220	Antiproliferative activity against human MOLM-13 cells harboring FLT3 ITD mutant assessed as inhibition of cell growth Antiproliferative activity against human MOLM-13 cells harboring FLT3 ITD mutant assessed as inhibition of cell growth	[PMID: 37163951]
MOLM-13	GI₅₀	0.001 μM Compound: Quizartinib	Antiproliferative activity against FLT3-dependent human MOLM-13 cells assessed as cell growth inhibition incubated for 72 hrs by resorufin dye based fluorescence analysis Antiproliferative activity against FLT3-dependent human MOLM-13 cells assessed as cell growth inhibition incubated for 72 hrs by resorufin dye based fluorescence analysis	[PMID: 37535845]
MOLM-13	GI₅₀	0.004 μM Compound: Quizartinib	Antiproliferative activity against human MOLM-13 cells harboring FLT3-ITD mutant assessed as cell growth inhibition by resorufin dye based fluorescence analysis Antiproliferative activity against human MOLM-13 cells harboring FLT3-ITD mutant assessed as cell growth inhibition by resorufin dye based fluorescence analysis	[PMID: 37535845]
MOLM-13	GI₅₀	0.067 μM Compound: Quizartinib	Antiproliferative activity against drug-resistant human MOLM-13 cells expressing FLT3-ITD-D835Y mutant assessed as cell growth inhibition incubated for 72 hrs by resorufin dye based fluorescence analysis Antiproliferative activity against drug-resistant human MOLM-13 cells expressing FLT3-ITD-D835Y mutant assessed as cell growth inhibition incubated for 72 hrs by resorufin dye based fluorescence analysis	[PMID: 37535845]
MOLM-13	IC₅₀	1230.5 nM Compound: Quizartinib	Antiproliferative activity against Sunitinib-resistant human MOLM-13 cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against Sunitinib-resistant human MOLM-13 cells incubated for 48 hrs by CCK8 assay	[PMID: 38655686]
MOLM-13	IC₅₀	39.4 nM Compound: Quizartinib	Antiproliferative activity against human MOLM-13 cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against human MOLM-13 cells incubated for 48 hrs by CCK8 assay	[PMID: 38655686]
MOLM-13	IC₅₀	40943.7 nM Compound: Quizartinib	Antiproliferative activity against Quizartinib-resistant human MOLM-13 cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against Quizartinib-resistant human MOLM-13 cells incubated for 48 hrs by CCK8 assay	[PMID: 38655686]
MOLM-14	GI₅₀	<0.0003 μM Compound: 7	Antiproliferative activity against human MOLM14 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MOLM14 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
MOLM-14	GI₅₀	<0.3 nM Compound: 7	Antiproliferative activity against human MOLM14 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MOLM14 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
MOLM-14	GI₅₀	0.23 nM Compound: 5	Antiproliferative activity against human MOLM14 cells harboring ITD mutant assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MOLM14 cells harboring ITD mutant assessed as cell growth inhibition by MTT assay	[PMID: 32272419]
MOLM-14	GI₅₀	1.35 nM Compound: 5	Antiproliferative activity against wild type human MOLM14 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against wild type human MOLM14 cells assessed as cell growth inhibition by MTT assay	[PMID: 32272419]
MOLM-14	GI₅₀	13.58 nM Compound: 5	Antiproliferative activity against human MOLM14 cells harboring ITD/F691L mutant assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MOLM14 cells harboring ITD/F691L mutant assessed as cell growth inhibition by MTT assay	[PMID: 32272419]
MOLM-14	GI₅₀	6.72 nM Compound: 5	Antiproliferative activity against human MOLM14 cells harboring ITD/D835Y mutant assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MOLM14 cells harboring ITD/D835Y mutant assessed as cell growth inhibition by MTT assay	[PMID: 32272419]
MOLM-14	GI₅₀	0.012 μM Compound: Quizartinib	Antiproliferative activity against human MOLM-14 cells harboring FLT3-ITD D835Y mutant assessed as cell growth inhibition by resazurin assay Antiproliferative activity against human MOLM-14 cells harboring FLT3-ITD D835Y mutant assessed as cell growth inhibition by resazurin assay	[PMID: 34479037]
MOLM-14	GI₅₀	0.027 μM Compound: Quizartinib	Antiproliferative activity against human MOLM-14 cells harboring FLT3-ITD F691L mutant assessed as cell growth inhibition by resazurin assay Antiproliferative activity against human MOLM-14 cells harboring FLT3-ITD F691L mutant assessed as cell growth inhibition by resazurin assay	[PMID: 34479037]
MOLM-14	GI₅₀	0.00015 μM Compound: Quizartinib	Antiproliferative activity against human MOLM-14 cells harboring FLT3-ITD mutant assessed as cell growth inhibition by resazurin assay Antiproliferative activity against human MOLM-14 cells harboring FLT3-ITD mutant assessed as cell growth inhibition by resazurin assay	[PMID: 34479037]
MOLM-14	GI₅₀	0.15 nM Compound: Quizartinib	Antiproliferative activity against human MOLM-14 cells harboring FLT3-ITD mutant assessed as cell growth inhibition by resazurin assay Antiproliferative activity against human MOLM-14 cells harboring FLT3-ITD mutant assessed as cell growth inhibition by resazurin assay	[PMID: 34479037]
MOLT-4	IC₅₀	50.281 μM Compound: AC220	Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
MONO-MAC-6	IC₅₀	0.004 nM Compound: 7; AC220	Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
MV4-11	IC₅₀	0.56 nM Compound: AC220	Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay	[PMID: 19654408]
MV4-11	IC₅₀	0.56 nM Compound: 7, AC220	Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer-blue cell viability assay Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer-blue cell viability assay	[PMID: 19754199]
MV4-11	GI₅₀	3.31 μM Compound: AC220	Growth inhibition of human MV411 cells after 48 hrs by XTT assay Growth inhibition of human MV411 cells after 48 hrs by XTT assay	[PMID: 25108079]
MV4-11	GI₅₀	0.003 μM Compound: 3, AC220	Inhibition of FLT3 ITD homozygous mutant in human MV4-11 cells assessed as cell growth inhibition after 72 hrs by MTS assay Inhibition of FLT3 ITD homozygous mutant in human MV4-11 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 26081023]
MV4-11	IC₅₀	0.68 nM Compound: AC220	Cytotoxicity against human MV4-11 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MV4-11 cells incubated for 72 hrs by MTT assay	[PMID: 26142317]
MV4-11	GI₅₀	1.103 μM Compound: AC220	Growth inhibition of human MV4-11 cells expressing FLT3-ITD after 48 hrs by XTT assay Growth inhibition of human MV4-11 cells expressing FLT3-ITD after 48 hrs by XTT assay	[PMID: 27187860]
MV4-11	IC₅₀	26 nM Compound: AC220	Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant after 72 hrs by MTT assay	[PMID: 27266526]
MV4-11	GI₅₀	1.103 μM Compound: AC220	Growth inhibition of human MV4-11 cells harboring FLT3-ITD mutant by XTT assay Growth inhibition of human MV4-11 cells harboring FLT3-ITD mutant by XTT assay	[PMID: 28043794]
MV4-11	GI₅₀	<0.0003 μM Compound: 7	Antiproliferative activity against human MV4-11 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MV4-11 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
MV4-11	GI₅₀	<0.3 nM Compound: 7	Antiproliferative activity against human MV4-11 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MV4-11 cells after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
MV4-11	GI₅₀	0.003 μM Compound: Quiz	Growth inhibition of human MV4-11 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of human MV4-11 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
MV4-11	IC₅₀	0.452 nM Compound: AC220	Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant measured after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant measured after 72 hrs by MTT assay	[PMID: 30939008]
MV4-11	IC₅₀	0 μM Compound: AC220	Antiproliferative activity against human MV4-11 cells harboring FLT3 ITD mutant assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human MV4-11 cells harboring FLT3 ITD mutant assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31614258]
MV4-11	IC₅₀	0.005 nM Compound: 7; AC220	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
MV4-11	IC₅₀	0.56 nM Compound: Quizartinib	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay	[PMID: 32659083]
MV4-11	GI₅₀	1 nM Compound: 3	Inhibition of FLT3 ITD mutant expressed in human MV4-11 cells assessed as reduction in cell growth incubated for 72 hrs by CCK8 assay Inhibition of FLT3 ITD mutant expressed in human MV4-11 cells assessed as reduction in cell growth incubated for 72 hrs by CCK8 assay	[PMID: 32832025]
MV4-11	IC₅₀	0.836 nM Compound: AC220	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability	[PMID: 32898697]
MV4-11	IC₅₀	0.002 μM Compound: Quizartinib	Antiproliferative activity against human MV4-11 cells assessed as cell death measured after 72 hrs by resazurin dye based assay Antiproliferative activity against human MV4-11 cells assessed as cell death measured after 72 hrs by resazurin dye based assay	[PMID: 34288692]
MV4-11	IC₅₀	0.5 nM Compound: Quizartinib	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 34583130]
MV4-11	IC₅₀	0.62 nM Compound: Quizartinib	Anticancer activity against human MV4-11 cells expressing homozygous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay Anticancer activity against human MV4-11 cells expressing homozygous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay	[PMID: 35033885]
MV4-11	GI₅₀	0.01 μM Compound: Quizartinib	Antiproliferative activity against human MV4-11 cells expressing FLT3-ITD mutant Antiproliferative activity against human MV4-11 cells expressing FLT3-ITD mutant	[PMID: 35124201]
MV4-11	IC₅₀	0.003 μM Compound: AC220	Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
MV4-11	IC₅₀	0.21 nM Compound: Quizartinib	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 36638621]
MV4-11	IC₅₀	5.3 nM Compound: AC220	Antiproliferative activity against human MV4-11 cells harboring FLT3 ITD mutant assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against human MV4-11 cells harboring FLT3 ITD mutant assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay	[PMID: 37163951]
MV4-11	GI₅₀	0.003 μM Compound: Quizartinib	Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant assessed as cell growth inhibition by resorufin dye based fluorescence analysis Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant assessed as cell growth inhibition by resorufin dye based fluorescence analysis	[PMID: 37535845]
MV4-11	IC₅₀	0.24 nM Compound: Quizartinib	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay	[PMID: 37584545]
MV4-11	IC₅₀	0.31 nM Compound: Quizartinib	Antiproliferative activity against human MV4-11 cells expressing FLT3 ITD/TKD mutant incubated for 72 hrs by absorbance based microplate reader Antiproliferative activity against human MV4-11 cells expressing FLT3 ITD/TKD mutant incubated for 72 hrs by absorbance based microplate reader	[PMID: 38389894]
MV4-11	IC₅₀	33.7 nM Compound: Quizartinib	Antiproliferative activity against human MV4-11 cells expressing FLT3-ITD mutant incubated for 48 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells expressing FLT3-ITD mutant incubated for 48 hrs by CCK8 assay	[PMID: 38655686]
NB-4	GI₅₀	7.3 μM Compound: 7	Antiproliferative activity against human NB4 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human NB4 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
NB-4	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human NB-4 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human NB-4 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
NB-4	GI₅₀	>3000 nM Compound: 3	Cytotoxicity against human NB4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity against human NB4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 32832025]
NOMO-1	IC₅₀	0.038 nM Compound: 7; AC220	Cytotoxicity against human NOMO-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human NOMO-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
NOMO-1	IC₅₀	>100 μM Compound: AC220	Antiproliferative activity against human NOMO-1 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human NOMO-1 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
OCI-AML2	GI₅₀	>10 μM Compound: 7	Antiproliferative activity against human OCI-AML2 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human OCI-AML2 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
OCI-AML2	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human OCI-AML2 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human OCI-AML2 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
OCI-AML2	IC₅₀	0.45 μM Compound: AC220	Antiproliferative activity against human OCI-AML2 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human OCI-AML2 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
OCI-AML-5	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human OCI-AML5 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human OCI-AML5 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
OPM-2	IC₅₀	0.056 nM Compound: 7; AC220	Cytotoxicity against human OPM-2 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human OPM-2 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
PBL	GI₅₀	>10 μM Compound: AC220	Cytotoxicity in human PBL cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity in human PBL cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35339838]
PBL	GI₅₀	8.6 μM Compound: AC220	Cytotoxicity in phyto-hematoagglutinin induced human PBL cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity in phyto-hematoagglutinin induced human PBL cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35339838]
PBMC	IC₅₀	1260.1 nM Compound: AC220	Cytotoxicity against human PBMC cells assessed as inhibition of cell growth Cytotoxicity against human PBMC cells assessed as inhibition of cell growth	[PMID: 37163951]
PBMC	IC₅₀	>20 μM Compound: Quizartinib	Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Aqueous One Solution Cell Proliferation Assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Aqueous One Solution Cell Proliferation Assay	[PMID: 37584545]
Rec1	IC₅₀	>20 μM Compound: Quizartinib	Antiproliferative activity against human REC1 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay Antiproliferative activity against human REC1 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay	[PMID: 37584545]
RPMI-8226	IC₅₀	0.184 nM Compound: 7; AC220	Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
RS4-11	IC₅₀	1.1 nM Compound: AC220	Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay	[PMID: 19654408]
RS4-11	IC₅₀	4.2 nM Compound: AC220	Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay	[PMID: 19654408]
Sf21	IC₅₀	26.08 nM Compound: AC220	Inhibition of recombinant human FLT3 expressed in insect Sf21 cells preincubated for 15 mins followed by poly(Glu:Tyr) substrate addition for 30 mins in presence of [gamma-32P]ATP by TR-FRET assay Inhibition of recombinant human FLT3 expressed in insect Sf21 cells preincubated for 15 mins followed by poly(Glu:Tyr) substrate addition for 30 mins in presence of [gamma-32P]ATP by TR-FRET assay	[PMID: 27187860]
Sf9	IC₅₀	>10 μM Compound: 3, AC220	Inhibition of recombinant GST-tagged Aurora-A kinase domain (S123 to S401) (unknown origin) expressed in insect Sf9 cells using tetra(LRRASLG) peptide as substrate after 90 mins by Kinase-Glo assay Inhibition of recombinant GST-tagged Aurora-A kinase domain (S123 to S401) (unknown origin) expressed in insect Sf9 cells using tetra(LRRASLG) peptide as substrate after 90 mins by Kinase-Glo assay	[PMID: 26081023]
Sf9	IC₅₀	0.069 μM Compound: 3, AC220	Inhibition of wild type GST-tagged FLT3 kinase domain (Y567 to S993) (unknown origin) expressed in baculovirus infected insect Sf9 cells using Her2 peptide as substrate after 4 hrs by Kinase-Glo assay Inhibition of wild type GST-tagged FLT3 kinase domain (Y567 to S993) (unknown origin) expressed in baculovirus infected insect Sf9 cells using Her2 peptide as substrate after 4 hrs by Kinase-Glo assay	[PMID: 26081023]
Sf9	IC₅₀	0.43 μM Compound: 3, AC220	Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay	[PMID: 26081023]
Sf9	IC₅₀	0.042 μM Compound: Quizartinib	Inhibition of recombinant human 3C cleavage site/N-terminal GST-His6 fused PDGFR alpha C-terminal fragment (Q551 to L1089 residues) harboring V561D mutant expressed in baculovirus infected Sf9 insect cells using AGLT peptide as substrate in presence of [g Inhibition of recombinant human 3C cleavage site/N-terminal GST-His6 fused PDGFR alpha C-terminal fragment (Q551 to L1089 residues) harboring V561D mutant expressed in baculovirus infected Sf9 insect cells using AGLT peptide as substrate in presence of [g	[PMID: 31514019]
Sf9	IC₅₀	19.8 nM Compound: 3	Inhibition of recombinant human N-terminal GST/His6-tagged FLT3 ITD mutant (571 to 993 residues) expressed in Sf9 cells using Tyr2 peptide as substrate incubated for 1.5 hrs by Z'-LYTE assay Inhibition of recombinant human N-terminal GST/His6-tagged FLT3 ITD mutant (571 to 993 residues) expressed in Sf9 cells using Tyr2 peptide as substrate incubated for 1.5 hrs by Z'-LYTE assay	[PMID: 32832025]
SKM-1	GI₅₀	1.3 μM Compound: 7	Antiproliferative activity against human SKM1 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human SKM1 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
SKM-1	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human SKM-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human SKM-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
TF-1	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human TF-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human TF-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
THP-1	GI₅₀	5.574 μM Compound: AC220	Growth inhibition of human THP1 cells after 48 hrs by XTT assay Growth inhibition of human THP1 cells after 48 hrs by XTT assay	[PMID: 25108079]
THP-1	GI₅₀	2.125 μM Compound: AC220	Growth inhibition of human THP1 cells expressing wild type FLT-3 after 48 hrs by XTT assay Growth inhibition of human THP1 cells expressing wild type FLT-3 after 48 hrs by XTT assay	[PMID: 27187860]
THP-1	GI₅₀	2.125 μM Compound: AC220	Growth inhibition of human THP1 cells harboring wild-type FLT3 by XTT assay Growth inhibition of human THP1 cells harboring wild-type FLT3 by XTT assay	[PMID: 28043794]
THP-1	GI₅₀	>20 μM Compound: Quiz	Growth inhibition of human THP1 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of human THP1 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
THP-1	IC₅₀	30 nM Compound: 7; AC220	Cytotoxicity against human THP-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human THP-1 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
THP-1	IC₅₀	>100 μM Compound: AC220	Antiproliferative activity against human THP-1 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay Antiproliferative activity against human THP-1 cells assessed as cell growth inhibition measured upto 4 hrs by CellTiter-Blue cell viability assay	[PMID: 35339838]
THP-1	IC₅₀	201.1 nM Compound: AC220	Antiproliferative activity against human THP-1 cells expressing wild type FLT3 assessed as inhibition of cell growth Antiproliferative activity against human THP-1 cells expressing wild type FLT3 assessed as inhibition of cell growth	[PMID: 37163951]
U-266	IC₅₀	19.65 nM Compound: 7; AC220	Cytotoxicity against human U-266 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay Cytotoxicity against human U-266 cells assessed as reduction in cell viability after 4 days by CellTiter-Blue assay	[PMID: 32199135]
U-937	GI₅₀	>20 μM Compound: 3, AC220	Cytotoxicity against FLT3-deficient human U937 cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against FLT3-deficient human U937 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 26081023]
U-937	GI₅₀	1.2 μM Compound: 7	Antiproliferative activity against human U937 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human U937 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay	[PMID: 28956923]
U-937	GI₅₀	>20 μM Compound: Quiz	Growth inhibition of human U937 cells after 72 hrs by calcein AM dye-based fluorescence assay Growth inhibition of human U937 cells after 72 hrs by calcein AM dye-based fluorescence assay	[PMID: 29672049]
U-937	IC₅₀	8.55 μM Compound: AC220	Antiproliferative activity against human U937 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human U937 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31614258]
U-937	GI₅₀	>3000 nM Compound: 3	Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 32832025]
U-937	IC₅₀	251.2 nM Compound: AC220	Antiproliferative activity against human U-937 cells expressing low level wild type FLT3 assessed as inhibition of cell growth Antiproliferative activity against human U-937 cells expressing low level wild type FLT3 assessed as inhibition of cell growth	[PMID: 37163951]
WI-38	IC₅₀	>10000 nM Compound: AC220	Antiproliferative activity against human WI38 cells after 72 hrs by SRB assay Antiproliferative activity against human WI38 cells after 72 hrs by SRB assay	[PMID: 27266526]
WI-38	IC₅₀	>20 μM Compound: Quizartinib	Cytotoxicity against human WI-38 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Aqueous One Solution Cell Proliferation Assay Cytotoxicity against human WI-38 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Aqueous One Solution Cell Proliferation Assay	[PMID: 37584545]

In Vitro

Quizartinib (0-10,000 nM; 48 h) potently inhibits proliferation of leukemia cell lines dependent on FLT3^ITD, FIP1L1-PDGFRA, or select KIT mutations (V560G, N822K, D814Y) with IC₅₀ values ranging from <1 nM to 77 nM^[1].
Quizartinib (0-10,000 nM; 48 h) potently inhibits proliferation and induces apoptosis in isogenic Ba/F3 cells expressing FLT3^WT, FLT3^ITD, FLT3^K663Q, FLT3^D835Y, KIT^WT, or KIT^D816Y with IC₅₀ values ranging from <1 nM to 474 nM^[1].
Quizartinib (0-1000 nM; 90 min) selectively inhibits autophosphorylation of mutant KIT^D816Y, KIT and FLT3^ITD, FLT3^D835Y isoforms in isogenic Ba/F3 cells, while KIT^D816V and FLT3^D835V are largely resistant to dephosphorylation^[1].
Quizartinib (0-5000 nM; 48 h) inhibits proliferation of native AML blasts with wild-type KIT, FLT3 amplification, or select FLT3 ITD mutations, while FLT3 ITD-beta1-positive blasts are insensitive^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Western Blot Analysis^[1]

View Protocol

Cell Line:

isogenic Ba/F3 cells stably transfected with mutant KIT (D816V, D816Y, D816F) or FLT3 (ITD, D835V, D835Y)
Concentration:

0, 10, 100, 1000 nM
Incubation Time:

90 min
Result:

Inhibited autophosphorylation of KIT^D816Y and KIT^D816F in the nanomolar range.
Caused dephosphorylation of both glycosylated and intracellular isoforms of KIT^D816Y, while dephosphorylation of KIT^D816F was restricted to the glycosylated isoform.
Showed no significant reduction in phosphorylation of KIT^D816V.
Inhibited autophosphorylation of FLT3 ITD and FLT3^D835Y.
Caused minimal inhibition of FLT3^D835V phosphorylation.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 950769-58-1
Appearance Solid
Masse moléculaire 560.67
Formule C₂₉H₃₂N₆O₄S
Color White to light yellow
SMILES

O=C(NC1=NOC(C(C)(C)C)=C1)NC2=CC=C(C=C2)C3=CN4C(SC5=CC(OCCN6CCOCC6)=CC=C45)=N3
Synonyms

AC220
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (49)

All WB

Sort by:

Journal Impact Factor

Cancer Cell

Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones. [Abstract]

2018 Oct 8;34(4):674-689.e8. PMID: 30245083
Cancer Cell

SYK is a critical regulator of FLT3 in acute myeloid leukemia. [Abstract]

2014 Feb 10;25(2):226-42. PMID: 24525236

Quizartinib purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2014 Feb 10;25(2):226-42. [Abstract]

Western blot for indicated proteins on lysates from FLT3-ITD-positive primary murine cells expressing either wild-type (WT) or constitutive active (SYK-TEL) SYK and treated for eight hours with indicated doses of AC220.
Immunity

Activating an interleukin 4-FLT3-STAT6 axis in multipotent progenitors restores lymphopoiesis in inflammation and aging. [Abstract]

2026 May 29:S1074-7613(26)00180-9. PMID: 42214327
Cancer Discov

C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia. [Abstract]

2023 Jul 7;13(7):1720-1747. PMID: 37012202
Nat Cancer

Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule. [Abstract]

2024 Jul;5(7):1082-1101. PMID: 38816660
Cancer Res

Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia. [Abstract]

2025 Nov 21:10.1158/0008-5472.CAN-24-3753. PMID: 41270153
Autophagy

Inhibition of PINK1 senses ROS signaling to facilitate neuroblastoma cell pyroptosis. [Abstract]

2025 Oct;21(10):2091-2110. PMID: 40160153
Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Nat Commun

Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials. [Abstract]

2018 Jan 24;9(1):358. PMID: 29367740
Exp Hematol Oncol

IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response. [Abstract]

2025 Feb 15;14(1):15. PMID: 39955584
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Acta Pharm Sin B

Synergistic effects of autophagy/mitophagy inhibitors and magnolol promote apoptosis and antitumor efficacy. [Abstract]

2021 Dec;11(12):3966-3982. PMID: 35024319
Blood Cancer J

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. [Abstract]

2025 Mar 15;15(1):40. PMID: 40089460
Cell Death Dis

Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. [Abstract]

2025 Dec 23. PMID: 41436723
Cell Death Dis

Targeting oncogenic activation of FLT3/SREBP/FASN promotes the therapeutic effect of quizartinib involving disruption of mitochondrial phospholipids. [Abstract]

2025 Apr 22;16(1):327. PMID: 40263296
Cell Commun Signal

Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis. [Abstract]

2024 Aug 7;22(1):391. PMID: 39113090
Cell Commun Signal

Identification of novel SCD1 inhibitor alleviates nonalcoholic fatty liver disease: critical role of liver-adipose axis. [Abstract]

2023 Sep 30;21(1):268. PMID: 37777801
Phytomedicine

Regulatory mechanism of perinatal nonylphenol exposure on cardiac mitochondrial autophagy and the PINK1/Parkin signaling pathway in male offspring rats. [Abstract]

2024 Apr:126:155434. PMID: 38367424
Acta Pharmacol Sin

Concurrent inhibition of p300/CBP and FLT3 enhances cytotoxicity and overcomes resistance in acute myeloid leukemia. [Abstract]

2025 May;46(5):1390-1403. PMID: 39885312
Oncogene

Transgenic IDH2R172K and IDH2R140Q zebrafish models recapitulated features of human acute myeloid leukemia. [Abstract]

2023 Apr;42(16):1272-1281. PMID: 36739363
Leukemia

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. [Abstract]

2012 Oct;26(10):2233-44. PMID: 22469781
EMBO J

SUCLG1 restricts POLRMT succinylation to enhance mitochondrial biogenesis and leukemia progression. [Abstract]

2024 Jun;43(12):2337-2367. PMID: 38649537
Haematologica

MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin. [Abstract]

2018 Nov;103(11):1862-1872. PMID: 29976747
Br J Cancer

Repurposing chlorpromazine for the treatment of triple-negative breast cancer growth and metastasis based on modulation of mitochondria-mediated apoptosis and autophagy/mitophagy. [Abstract]

2025 Apr 11. PMID: 40217096
Cell Rep

Bone marrow mesenchymal stromal cells support translation in refractory acute myeloid leukemia. [Abstract]

2025 Jan 28;44(1):115151. PMID: 39932190
J Med Chem

3 H-Pyrazolo[4,3- f]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo. [Abstract]

2021 Aug 12;64(15):10981-10996. PMID: 34288692
J Med Chem

Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML. [Abstract]

2017 Oct 26;60(20):8407-8424. PMID: 28956923

Quizartinib purchased from MedChemExpress. Usage Cited in: J Med Chem. 2017 Oct 26;60(20):8407-8424. [Abstract]

Doseresponsive immunoblotting of the signaling pathway with the cells extracted from tumor tissues of the experimental animal after the 14 and 7 (AC220) treatments.
Mol Cancer Ther

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. [Abstract]

2015 Oct;14(10):2249-59. PMID: 26206331
J Ethnopharmacol

Rexiao Kuining decoction ameliorates ulcerative colitis by restoring immune homeostasis via the protein kinase C alpha-FMS-like tyrosine kinase 3 ligand axis: multi-omics evidence. [Abstract]

2026 Nov 15:370:121985. PMID: 42264446
Mol Syst Biol

Illuminating phenotypic drug responses of sarcoma cells to kinase inhibitors by phosphoproteomics. [Abstract]

2024 Jan;20(1):28-55. PMID: 38177929
Ecotoxicol Environ Saf

Mechanistic study on nonylphenol-induced liver fibrosis via Pink1/Parkin-mediated mitophagy and lipid droplet degradation in hepatic stellate cells. [Abstract]

2025 Oct 15:305:119206. PMID: 41106202
Mol Cancer Res

GATM-Mediated Creatine Biosynthesis Enables Maintenance of FLT3-ITD-Mutant Acute Myeloid Leukemia. [Abstract]

2022 Feb;20(2):293-304. PMID: 34635505
Eur J Pharmacol

Quizartinib-induced resistance drives clonal emergence of MV4-11 cells with molecular alterations enabling multidrug antileukemic escape. [Abstract]

2026 May 10:1023:178877. PMID: 41997407
Int Immunopharmacol

FLT3+ DC inhibits immune rejection via interaction with Treg in liver transplantation. [Abstract]

2024 Aug 20:137:112289. PMID: 38889505
FASEB J

Activation of FMS-like tyrosine kinase 3 protects against isoprenaline-induced cardiac hypertrophy by improving autophagy and mitochondrial dynamics. [Abstract]

2022 Dec;36(12):e22672. PMID: 36440960
Microb Pathog

mTORC2-dependent autophagy inhibition regulates the replication of HSV-1 and adenovirus in viral keratitis & conjunctivitis. [Abstract]

2026 Apr:213:108349. PMID: 41628839
Br J Haematol

Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. [Abstract]

2019 Nov;187(4):488-501. PMID: 31309543
Vaccines

Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8+ T Cells. [Abstract]

2021 Nov 8;9(11):1294. PMID: 34835225
PLoS One

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. [Abstract]

2013;8(2):e56473. PMID: 23437141
bioRxiv

2026 Jul 22:2026.07.21.736123. PMID: 42539318
bioRxiv

2025 Sep 21.
SSRN

2025 Feb 13.
bioRxiv

2024 October 25.
Patent

US20240277715A1.
Comput Biol Med

Synergy and antagonism between azacitidine and FLT3 inhibitors. [Abstract]

2024 Feb:169:107889. PMID: 38199214
Univerzita Karlova v Praz

2021 Jul.
Oncotarget

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. [Abstract]

2017 Jun 28;8(40):67639-67650. PMID: 28978059
Oncotarget

Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. [Abstract]

2016 Jul 26;7(30):47018-47032. PMID: 27331411

Quizartinib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 Jul 26;7(30):47018-47032. [Abstract]

A. The established 32D cells are treated with Quizartinib for 2h, followed by 10 ng/mL FL stimulation for 10 minutes. Wt-FLT3 and mutant FLT3 are immunoprecipitated by each tag as indicated and subjected to Western blot. Phosphorylation levels of FLT3, STAT5, AKT and MAPK are examined. B. 32D cells are treated with Quizartinib at the indicated concentrations in the presence or absence of 10 ng/mL FL for 2 hours. Phosphorylation levels of FLT3, STAT5, AKT and MAPK are detected by Western blot.
Leiden University

2019 Mar.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (178.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

DMF : 10 mg/mL (17.84 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7836 mL

8.9179 mL

17.8358 mL

5 mM

0.3567 mL

1.7836 mL

3.5672 mL

10 mM

0.1784 mL

0.8918 mL

1.7836 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMF 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1 mg/mL (1.78 mM); Clear solution

Protocol 2

Add each solvent one by one: 10% DMF 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1 mg/mL (1.78 mM); Clear solution

Protocol 3

Add each solvent one by one: 10% DMF 90% Corn Oil

Solubility: 1 mg/mL (1.78 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

All Signal Pathway Related Cell Biology

Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of ³²P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (274 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Kampa-Schittenhelm KM, et al. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol Cancer. 2013;12:19. Published 2013 Mar 7. [Content Brief]

[2]. Cortes J, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19(7):889-903. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMF / DMSO	1 mM	1.7836 mL	8.9179 mL	17.8358 mL	44.5895 mL
	5 mM	0.3567 mL	1.7836 mL	3.5672 mL	8.9179 mL
	10 mM	0.1784 mL	0.8918 mL	1.7836 mL	4.4590 mL
	15 mM	0.1189 mL	0.5945 mL	1.1891 mL	2.9726 mL
DMSO	20 mM	0.0892 mL	0.4459 mL	0.8918 mL	2.2295 mL
	25 mM	0.0713 mL	0.3567 mL	0.7134 mL	1.7836 mL
	30 mM	0.0595 mL	0.2973 mL	0.5945 mL	1.4863 mL
	40 mM	0.0446 mL	0.2229 mL	0.4459 mL	1.1147 mL
	50 mM	0.0357 mL	0.1784 mL	0.3567 mL	0.8918 mL
	60 mM	0.0297 mL	0.1486 mL	0.2973 mL	0.7432 mL
	80 mM	0.0223 mL	0.1115 mL	0.2229 mL	0.5574 mL
	100 mM	0.0178 mL	0.0892 mL	0.1784 mL	0.4459 mL

Bioz

Quizartinib

49 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Quizartinib

Publications Citing Use of MedChemExpress (MCE) Quizartinib

Voir tous les produits spécifiques à Isoform PDGFR